ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.068,21
0,26%
S&P 500
5.442,40
0,20%
Dow Jones
38.602,00
0,03%
Euro vs US Dollar
1,07211
0,18%
Bitcoin
65.487,27
-1,73%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Pardes Biosciences Inc (PRDS)

  7. Pardes Biosciences Inc (PRDS) News

PRDS

Pardes Biosciences (PRDS)

Pardes Biosciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PRDS
DatumZeitQuelleÜberschriftSymbolFirma
11/09/202314h00Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:PRDSPardes Biosciences Inc
31/08/202323h17Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202320h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRDSPardes Biosciences Inc
31/08/202320h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRDSPardes Biosciences Inc
31/08/202315h06Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PRDSPardes Biosciences Inc
31/08/202315h03Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PRDSPardes Biosciences Inc
31/08/202315h01Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PRDSPardes Biosciences Inc
31/08/202314h59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRDSPardes Biosciences Inc
31/08/202314h53Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202314h34Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202314h30Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202314h15GlobeNewswire Inc.Pardes Biosciences Announces Closing of Tender OfferNASDAQ:PRDSPardes Biosciences Inc
28/08/202318h11Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:PRDSPardes Biosciences Inc
28/08/202318h08Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PRDSPardes Biosciences Inc
28/08/202317h52Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:PRDSPardes Biosciences Inc
28/08/202317h33Business WireMediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes BiosciencesNASDAQ:PRDSPardes Biosciences Inc
17/08/202323h43Business WireMediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences SharesNASDAQ:PRDSPardes Biosciences Inc
17/08/202323h11Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:PRDSPardes Biosciences Inc
17/08/202323h09Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PRDSPardes Biosciences Inc
17/08/202322h59Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:PRDSPardes Biosciences Inc
04/08/202322h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRDSPardes Biosciences Inc
04/08/202322h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRDSPardes Biosciences Inc
28/07/202323h08Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:PRDSPardes Biosciences Inc
28/07/202323h04Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:PRDSPardes Biosciences Inc
28/07/202323h01Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:PRDSPardes Biosciences Inc
17/07/202313h58Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:PRDSPardes Biosciences Inc
17/07/202313h55Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:PRDSPardes Biosciences Inc
17/07/202313h11Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:PRDSPardes Biosciences Inc
17/07/202313h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRDSPardes Biosciences Inc
17/07/202313h00GlobeNewswire Inc.Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value RightsNASDAQ:PRDSPardes Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:PRDS

Kürzlich von Ihnen besucht

NASDAQ
TSLA
Tesla
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
AMZN
Amazon.com
DBI
MDAX
MDAX
TG
MBG
MercedesBenz
TG
ALV
Allianz
TG
RHM
Rheinmetall
NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
SPY
SPDR S&P 500
CCOM
US100
US Tech 100
USOTC
ADDYY
Adidas (QX)
NASDAQ
NVDA
NVIDIA
NYSE
MCD
McDonalds
USOTC
DTEGY
Deutsche Telekom (QX)
FX
EURUSD
Euro vs US Dollar
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten